Zydus receives final approval from the USFDA for Micafungin for Injection

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Micafungin for Injection, 50 mg/vial and 100 mg/vial, single-dose vials (USRLD: Mycamine®).

Micafungin for Injection is indicated to treat variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Micafungin for Injection had annual sales of USD 99 mn in the United States according to IQVIA data (IQVIA MAT Aug 2022).

The group now has 329 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 413.15 as compared to the previous close of Rs. 409.95. The total number of shares traded during the day was 10804 in over 575 trades.

The stock hit an intraday high of Rs. 417.00 and intraday low of 412.10. The net turnover during the day was Rs. 4474354.00.

(*as of 30th June 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA FinalApproval Micafungin Injection